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Abstract
Background: Leishmania (L.) species are the causative agent of leishmaniasis. Due to the lack of efficient vaccine candidates,
drug therapies are the only option to deal with cutaneous leishmaniasis. Unfortunately, chemotherapeutic interventions
show high toxicity in addition to an increased risk of dissemination of drug-resistant parasites. An appropriate laboratory
animal based model is still missing which allows testing of new drug strategies in the context of human immune cells in
vivo.
Methodology/Principal Findings: Humanized mice were infected subcutaneously with stationary phase promastigote L.
major into the footpad. The human immune response against the pathogen and the parasite host interactions were
analyzed. In addition we proved the versatility of this new model to conduct drug research studies by the inclusion of orally
given Miltefosine. We show that inflammatory human macrophages get infected with Leishmania parasites at the site of
infection. Furthermore, a Leishmania-specific human-derived T cell response is initiated. However, the human immune
system is not able to prevent systemic infection. Thus, we treated the mice with Miltefosine to reduce the parasitic load.
Notably, this chemotherapy resulted in a reduction of the parasite load in distinct organs. Comparable to some Miltefosine
treated patients, humanized mice developed severe side effects, which are not detectable in the classical murine model of
experimental leishmaniasis.
Conclusions/Significance: This study describes for the first time L. major infection in humanized mice, characterizes the
disease development, the induction of human adaptive and innate immune response including cytokine production and
the efficiency of Miltefosine treatment in these animals. In summary, humanized mice might be beneficial for future
preclinical chemotherapeutic studies in systemic (visceral) leishmaniasis allowing the investigation of human immune
response, side effects of the drug due to cytokine production of activated humane immune cells and the efficiency of the
treatment to eliminate also not replicating (‘‘hiding’’) parasites.
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Introduction
Over the last decades inbred mice were used to investigate the
mechanisms of adaptive and innate immune responses against the
obligatory intracellular parasite Leishmania (L.) major. From these
studies fundamental paradigms regarding the elimination of the
parasites were generated [1]. It could be demonstrated that in
resistant C57BL/6 mice the elimination of intracellular parasites
depends on the induction of an interferon-c (IFN-c) -driven T
helper (Th) 1 immune responses. This Th1-associated cytokine
production is crucial for the activation of infected macrophages to
produce leishmanicidal pathways such as inducible nitric oxide
synthase (iNOS) and subsequently nitric oxide radicals (NO) [2]. In
contrast non-healing BALB/c mice mount a Th2 response
associated with high levels of IL-4 and IL-13 [3–5]. Of note, similar
to the experimental model, healing of cutaneous leishmaniasis in
humans is also associated with a Th1-type immune response [5].
However, leucocytes from humans and rodents vary in their
phenotype and function. For instance, the number of granulocytes
in peripheral blood, which are the first line of defense against
Leishmania infection, differs between human (50–70%) and mouse
(10–25%) [6]. Furthermore, the relevance of the leishmanicidal
molecules such as NO that is known to be substantially involved in
the elimination of L. major parasites in the murine model of
experimental leishmaniasis, is still not completely understood in
the human system [7–11]. This might be due to the fact that
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murine macrophages respond to classical iNOS-inducing stimuli
such as LPS and IFN-c with iNOS expression and accumulation
of NO whereas in humans alternative stimuli (such as IFN-a/b,
IL-4, and anti-CD23) appear to be more efficient for monocyte
and macrophage stimulation [2,12–13]. In addition antimicrobial
peptides e.g. defensins which have the potential to reduce
intracellular pathogens [14] differ in number, sequence, genomic
location, and activation between human and mice [2,12–13]. For
instance human defensins are present in human neutrophils but
not in mice [15] whereas the mouse Paneth cells in the crypts of
the small intestine express more than 20 different defensins but
only two defensins are described in human cells [16].
Furthermore, differences in the maturation and regulation of T
cells [17–18], in immunoglobulin subtypes, receptors, and their
function [18] impede the transfer of scientific results gained from
animal experiments to the human system.
NOD/scid-IL2Rc2/2 (NOG or NSG) mice were first described
and generated by crossing IL2Rc2/2 mice with NOD-scid mice
[19–20]. These mice lack not only B and T cells, but also feature
considerably higher engraftment rates with human hematopoietic
cells, extended lifespan, low levels of murine innate immunity and
no NK cell activity [21] compared to previous mouse models. Upon
transplantation of human CD34+ hematopoietic stem cells, NSG
mice develop all human subsets of the immune system like T, B, and
NK cells as well as myeloid cells and are able to mount an innate
and adaptive immune response to antigens [19,21,22]. Therefore,
mice bearing a human immune system might offer the opportunity
to bridge the gap between animal models and clinical studies and
are increasingly integrated in infectious disease studies and the
investigation of human medication and vaccine projects [23–33].
The present study characterizes the human immune response in
humanized mice after subcutaneous infection with L. major
parasites. Our data reveal that human macrophages harbor
Leishmania parasites. Unexpectedly, the parasitic replication was
not limited to the site of infection but also observed in visceral
organs such as spleen and liver. Although Leishmania-specific
human T cells were generated, the humanized mice succumbed to
the cutaneous infection.
To demonstrate the versatility of Leishmania-infected humanized
mice for future drug studies, we complemented the infection
studies with systemic Miltefosine treatment. Miltefosine efficiency
was first implemented in tumor treatments and later described as a
new line of drugs against Leishmania infections tested in humans
[34] and mice [35]. It amends the second line drugs of aromatic
diamidines, amphotericin B, and pentavalent antimonials which
induce rising resistance and are toxic with severe sometimes life-
threatening side effects [36].
In conclusion we could demonstrate that human immune cells
interact with protozoan parasites in a murine environment. This
novel experimental model might be beneficial for the investigation
of drug efficiency to eliminate the parasite in the context of human
immune cells possibly involved in severe side effects such as organ
damage.
Methods
Ethic statement
Cord blood samples were taken with approval from the Ethics
Committee of the University Regensburg (permission no. 08/021).
All patients included in the experiments provided written informed
consent. All experiments were performed in accordance with relevant
institutional and national guidelines, regulations and approvals.
Humanized mice
Mice (NOD-scid IL2Rcnull; (NSG)) used for the experiments
were obtained from Jackson Laboratories, and bred and kept in a
specialized pathogen-free facility. Newborn mice were transplant-
ed with 36105 CD34+ hematopoietic stem cells isolated from Cord
blood as described before [37]. Hematopoietic cells were injected
into the liver of neonatal mice. For infection studies, a total of 32
humanized mice, between three and five months of age were
analyzed for their reconstitution levels shortly before L. major
infection. All animal work was approved by the local veterinary
authorities from the district government of Upper Palatinate/
Bavaria based on the international European guidelines and
national regulations of the German animal protection act
(permission no. 54-2531.2-18/08).
Infection and Miltefosine application
Humanized mice were infected via s.c. injection of 36101–
36106 stationary phase promastigote L. major (MHOM/IL/81/
FE/BNI) parasite into the right hind footpad adjusted to a final
volume of 30 ml. BALB/c and C57BL/6 mice were infected with
36106 stationary phase promastigote L. major and served as
controls. Disease progression was monitored on a daily basis.
Footpad swelling and weight loss was monitored once a week.
Treatment survey was implemented by administering Miltefosine
(2.5 mg/kg; Cayman Chemical) orally on a daily basis using a
gavage tube starting two weeks post infection. This initial
condition of infection is important to mimic the scenario in L.
major patients before starting Miltefosine treatment.
Determination of parasite load using quantitative RT-PCR
Parasite load was determined using qPCR-analysis as described
before [38]. SYBR Green (BioRAD, Germany) was used for product
detection and quantified on total human-beta-actin 59-GGG TGT
AAC GCA ACT AAG TCA T-39 (forward) and 59-TGG ACA TCC
GCA AAG ACC TG-39 (reverse) or mouse ß-actin 59-GGA TGC
CAC AGG ATT CCA TAC CCA-39 (reverse) and 59-TCA CCC
ACA CTG TGC CCA TCT ACG A-39 (forward).
Amplification and detection were performed using the Multi-
color Real-Time PCR Detection System (BioRAD, Germany).
Author Summary
As many as 12 million people suffer from Leishmania (L.)
infection worldwide with about one to two million newly
infected people every year. Due to the lack of vaccine
strategies, the only option is chemotherapeutic interven-
tion which can cause serious side effects. Therefore, new
prevention or treatment strategies are urgently needed in
addition to an appropriate animal model for testing. We
infected humanized mice in the footpad with stationary
phase promastigote L. major and analyzed the human
innate and adaptive immune response by flow cytometry,
histology, and quantitative PCR. Infected macrophages
were detectable at the site of infection and in lymphoid
organs. Additionally, we were able to measure Leishmania-
specific T cell priming in humanized mice. However, these
human immune defense mechanisms were not sufficient
to prevent systemic spreading and lethality. By the
inclusion of Miltefosine, we tested this novel model for
its versatility in conducting drug studies. The oral
treatment was able to reduce parasitic load but also
revealed side effects which are described in humans but
not in mice. Therefore, we propose humanized mice as a
novel model, which offers the opportunity to study new
therapy strategies in chronic leishmaniasis in the context
of a human immune system.
Experimental Leishmaniasis in Humanized Mice
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Standards, samples and non template controls were analyzed in
triplicate for each run. As described in [38] the copies of Leishmania
DNA (Units) were determined within the desired samples. DNA
isolated from a distinct number of promastigote Leishmania
parasites were used to determine the number of parasites/Unit
Leishmania DNA. According to that internal standard we calculated
the number of parasites within the sample. The data are presented
as number of parasites/ng human b-actin (humanized mice) or
number of parasites/ng mouse b-actin (C57BL/6 and BALB/c
mice).
Mononuclear cell isolation from various tissues
For FACS analyses mononuclear cells were isolated from the
indicated tissues as previously described [37].
T cell proliferation and activation assay
Spleen cells from infected humanized mice (six weeks post
infection) and uninfected controls were isolated as described above
and labeled with Carboxyfluorescein succinimidyl ester (Invitrogen,
Oregon, USA) as described before [38]. For stimulation, 56105
cells/well from each individual mouse were incubated with lysed
L. major promastigote total antigen (ratio: ten parasites per cell),
PMA (final concentration 50 ng/ml), or with ConA (final concen-
tration 1 mg/ml) in microtiter plates in RPMI 1640 supplemented
with 10% FCS (Sigma), glutamine, Hepes, and Penicillin-Strepto-
mycin (Seromed-Biochrom, Berlin, Germany). After 72 h, cells
were harvested and the percentage of proliferating B cells, CD4+
and CD8+ T cells was determined by flow cytometry. For the
analysis of human cytokine production in L. major infected
humanized mice, spleen cells (three weeks post infection) were
harvested and re-stimulated as described above. Supernatants were
collected 72 hours later and the release of cytokines was measured
in a 5-colour-Multiplex Human Cytokine Panel-assay (Milllipore,
Billerica, MA, USA) according to manufacturer’s protocol.
Flow cytometry analysis
Reconstitution with human immune cells was determined by
flow cytometry using a LSR-II flow cytometer running the Diva
software package (BD Biosciences, San Jose, USA). To reduce
non-specific binding, cells were incubated with mouse and human
IgGs (10 ug/ml, Sigma) on ice for 10 minutes before staining with
human specific monoclonal antibodies (mAb) or appropriate
isotype mAb. Samples were stained using the following human
specific mAb: anti-CD3-FITC (IgG2ak, clone HIT3a), anti-
CD19-PE (IgG1k, Clone: HIB19), anti-CD33-PerCP-Cy5.5
(IgG1k, clone P67.6), anti-CD45-APC (IgG1k, clone HI30), anti-
CD4-PE (IgG1k, clone SK3), and anti-CD8-PE (IgG1k, clone
HIT8a) from BD Biosciences. For further characterization we used
anti-CD3-PerCP (IgG2a, clone OKT3), anti-HLA-DR-PE-Cy7
(IgG2bk clone LN3), anti-CD86-PE (IgG2bk clone IT2.2), anti-
CD45RA-PE-Cy7 (IgG2ak, clone HI100), and anti-CD27-Biotin
(IgG1k, clone O323) from eBioscience (San Diego, USA).
Immunofluorescence microscopy
Biopsies from organs of interest were embedded in Killik cryostat
embedding medium (BioOptica, Milano, Italy) and stored at
280uC. Cryo sections (7 mm) were thawed onto poly-L-Lysin slides
(Thermo Scientific, Germany) and processed as described before
[38]. The sections were first stained with rabbit-anti-L. major serum
in PBS/BSA and 0.1% saponin (Roth, Karlsruhe, Germany). After
washing in PBS containing 0.01% Tween-20, slides were incubated
with goat anti-rabbit AlexaFlour 546 (Invitrogen, Darmstadt,
Germany). The antibodies anti-hCD45 (APC) antibody (IgG1k,
clone HI30) and anti-hCD68-PE (IgG2bk, clone Y1/82A) were
used to stain for human leukocytes and macrophages. All antibodies
were tested for human-specificity on not humanized NSG mice.
Nuclei were stained using DAPI (Sigma-Aldrich, Deisenhofen,
Germany). After mounting with Permafluor (Thermo Scientific),
sections were analyzed using an immuno-fluorescence microscope
(Zeiss, Jena, Germany) equipped with high-sensitivity gray scale
digital camera (Openlab System; Improvision, Heidelberg, Ger-
many). Separate images were collected for each section, analyzed
and merged false-color afterwards. Final image processing was
performed using Adobe Photoshop Elements (Adobe Systems
GmbH, Mu¨nchen, Germany).
Liver damage
Alanin-aminotransferase (ALT/GPT), and aspartat-amino-
transferase (AST/GOT) were measured in serum using the
analytic instrument COBAS INTEGRA 800 (Roche Diagnostics,
Germany). Normal values published for mice: ALT = 17–77 (U/I)
and AST = 54–298 (U/I) and for humans: ALT =,50 and
AST =,50.
Nitric oxide synthase 2 (iNOS) mRNA expression analysis
Spleen and foot tissue or spleen cells were homogenized in a
Tissue Lyser (Qiagen, Hilden, Germany), total RNA was extracted
using the TriFast reagent (Peqlab, Erlangen, Germany) and
contaminating DNA was removed with DNase I (Ambion DNAfree,
Invitrogen, Karlsruhe, Germany). Subsequently, 2–5 mg RNA were
reverse transcribed using the High Capacity cDNA Reverse
Transcription Kit (Invitrogen). To assess the amount of iNOS
cDNA the Applied Biosystems HT7900 Taqman quantitative PCR
system (Invitrogen) was used. Human and mouse NOS2 cDNA was
measured in triplicates with the following gene-specific Applied
Biosystems Taqman assays (Invitrogen): huNOS2
(Hs01075529_m1), mNOS2 (Mm00440485_m1). The gene for
human glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
Hs02758991_g1) or for mouse hypoxanthine guanine phosphor-
ibosyl transferase-1 (HPRT-1, Mm00446968_m1) was used as
endogenous control for calibration of mRNA levels, respectively.
Quantitative analyses were performed using the SDS 2.3 software
(Applied Biosystems/Invitrogen). The mRNA levels were calculated
by the following formula: relative expression = 2-(CT(Target)-
CT(Endogenous control))6f, with f = 104 as an arbitrary factor.
Statistics
Statistical analysis was performed using Graph Pad’s Prism. All
data are represented as as mean 6 SEM, and were tested for
statistical significance using Student’s t test, ANOVA, Bonferroni
posttest, Log-rank or Tukey’s Multiple Comparison Test , as
indicated in the figure legends.
Results
Humanized mice infected with Leishmania major showed
dose-dependent footpad swelling and disease
progression
Shortly before infection humanized mice were tested for
efficient reconstitution with human immune cells (Figure S1). To
prove the concept that humanized mice develop a local inflam-
mation at the site of infection we infected them subcutaneously
with different numbers of L. major parasites. Depending on the
amount of parasites injected, differences in footpad swelling
(Figure 1A) and weight loss (Figure 1C) were found. Humanized
mice infected with a high dose (36106) of L. major showed an
Experimental Leishmaniasis in Humanized Mice
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earlier, massive weight loss starting at day 35 followed by
intermediate dose (36103) which resulted in a delayed, less
pronounced weight loss at day 49 post infection (Figure 1B). Due
to the severity of disease, some of the animals infected with 36106
or 36103 Leishmania parasites died between day 14 and day 49 and
the remaining mice were sacrificed at day 50 and 56, respectively
(Figure 1D). In contrast to the high dose infection, low dose
infection (36101) caused only a slight weight loss (Figure 1C) and
all mice survived until day 56 (Figure 1D). Non-infected
humanized mice served as controls and did not show any sign of
weight loss or disease and survived until day 56 on which they
were sacrificed (data not shown).
In comparison high dose (36106) infected BALB/c showed the
highest local inflammation reaction and had to be sacrificed after
day 29 (Figure 1B). Six weeks post infection, quantification of the
number of Leishmania parasites within the samples of humanized
mice revealed that the site of infection represents the organ with
the highest parasites load (Figure 1E). Visceral organs such as the
spleen and liver were also infected but with lower concentration of
parasites when normalized to human b-actin (Figure 1E). High
dose infected BALB/c showed also systemic spreading of the
parasites with the highest concentration in the footpad (Figure 1F).
Considering the high load of L. major parasites in the liver of
humanized mice, we assessed the liver damage by measuring the
levels of the liver enzymes Aspartat-Aminotransferase (AST/
GOT) and Alanin-Aminotransferase (ALT/GPT) in the serum.
These data revealed that humanized mice show an increase of
GOT (ø 541 U/l+/2220 SEM) and GPT (ø70 U/l+/219 SEM)
after infection with L. major compared to uninfected controls GOT
(ø 77,2 U/l+/26 SEM) and GPT (ø 21 U/l+/22,6 SEM). In
contrast, in resistant C57BL/6 mice (GOT: 88 U/l+/23 SEM;
GPT: 15 U/l+/20,6 SEM) as well as susceptible BALB/c (GOT:
198 U/l+/247 SEM; GPT: 71 U/l+/215 SEM) infected with L.
major parasites no signs of liver damage were detectable. Thus, only
humanized mice infected with L. major showed an increase in
GOT levels compared with normal values of GOT and GPT in
humans and mice (see Material & Method section).
Notably, these infection experiments clearly demonstrate that
humanized mice show signs of inflammation at the site of infection
indicating that they respond to the protozoan parasites L. major.
Furthermore, we show that comparable to some human patients
[39,40] humanized mice develop a mixture of cutaneous and
visceral manifestation of leishmaniasis. The cellular components
involved in that process are presented below.
Leishmania major parasite infestation of human cells in
the secondary lymphoid organs and at the site of
infection
To address the question whether human host cells are infected
with the parasites, immunohistological analyses were performed.
Consistent with the PCR data we were able to show that L. major
antigens were present in liver and spleen of humanized mice
(Figure 2A and B). Furthermore, L. major antigens were detectable
within human CD45+ hematopoietic cells (Figure 2A and 2B).
However, there are also murine macrophages and granulocytes
(hCD452 cells) still present in humanized mice [21]. Therefore,
one cannot exclude the possibility that besides human phagocytes,
mouse phagocytes were also infected with L. major parasites.
To determine the origin of the infected phagocytes in detail,
cryosections from infected footpads and from infected visceral organs
(e. g. spleen) were characterized. These data revealed that Leishmania-
antigens were detectable within nucleated cells (Figure 2C). More-
over, we confirmed that Leishmania-antigens were detectable in
CD68+ human macrophages (Figure 2C; insert CI) and CD682 cells
(Figure 2C; insert CII). However, randomized spot tests indicated
that over 80% of infected cells were human CD68+ macrophages
(data not shown). Thus we conclude that human macrophages as well
as mouse phagocytes can engulf Leishmania parasites within the
infected tissue of humanized mice.
To address the questions whether other myeloid-derived human
cells respond to the Leishmania-infection, antigen-presenting cells
such as dendritic cells (Lin2CD11c+HLA-DR+) were characterized
in infected humanized mice. These data demonstrate that activation
markers such as CD86 and HLA-DR were increased in humanized
mice infected with L. major compared to uninfected controls (Figure
S2 A–C). Therefore, we conclude that myeloid cells derived from
human stem cells interact and respond to the parasites in vivo.
For functional studies of the leishmanicidal capacity induced at
the side of infection and in visceral organs such as the spleen, we
analyzed the mRNA expression levels of human and murine
derived iNOS three weeks after infection. Naive humanized mice
showed a baseline expression of murine iNOS within the footpad
and spleen tissue which was significantly increased in the footpad
after the infection with L. major (Figure S2D) whereas no
alterations of mouse iNOS mRNA levels were observed in the
spleen. Human iNOS mRNA expression was below the detection
limit in all samples (Figure S2D). The fact that mouse iNOS is
induced upon infection further supports the idea that not only
human macrophages but also murine phagocytes get infected and
activated in humanized mice.
Leishmania major infection in humanized mice induced a
human-derived adaptive immune response at the site of
infection
L. major parasites disseminate within the humanized mice and
interact with human leukocytes. We further aimed to answer the
question whether the parasites or their corresponding antigens are
immunogenic in terms of being able to initiate an adaptive human-
derived immune response. From Leishmania-infected patients it is
known that macrophages represent the dominant cell population
within cutaneous lesions, followed by CD3+ T cells [41].
Considering our histological findings, demonstrating a dense
dermal infiltration of CD68+ macrophages building clusters in the
infected area (data not shown), we focused our interest on the
activation status of human lymphocytes. Comparable to the biopsy
data from patients suffering from cutaneous leishmaniasis [41], we
were able to show that CD3+ T cells dominate the lymphocyte
population at the site of infection whereas B cells represent the
minority of the skin-infiltrating lymphocytes (Figure 3B). Further
distinction of the invading CD3+ T cells into CD4+ T helper cells
versus CD8+ cytotoxic T cells revealed the dominance of the
CD4+ T cell population (Figure 3C). Additional analysis of the
infiltrating T cells illustrated a memory phenotype (CD27+
CD45RA2) of both T cell subpopulations (Figure 3D). This
increased population of memory phenotype indicates that T cell
activation took place after infection with L. major parasites.
Leishmania-specific T cells were generated in humanized
mice
Due to a relatively weak formation of lymph nodes and Peyer’s
patches in humanized mice [22], we analysed human lymphocytes
isolated from spleens of infected animals. The majority of immune
cells in the spleen were CD3+ T cells, mainly CD4+ (70%) in
infected humanized mice as well as in controls. Further analysis of
CD4+ and CD8+ T cells revealed that there was a significant
switch towards the memory phenotype (CD45RA2CD27+;
Figure 4A). As shown in Figure 4B, immune cells isolated from
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Figure 1. Humanized mice infected with Leishmania major showed dose dependent footpad swelling, weight loss, survival, and
parasite infestation. Humanized mice (A, C, E) and BALB/c (B, D, F) mice (at the age of 3 months) were infected with different numbers of L. major
parasites and were weekly monitored for footpad swelling (A; n = 11 and B n = 9), weight changes (C; n = 11), survival (D; n = 15). The amount of L.
major parasites was normalized to human b-actin in 36106 L. major infected humanized mice (D; n = 7 in spleen, liver, lung and bone marrow; n = 6 in
kidney; n = 4 in footpad; n = 3 in lymph node). Three 36106 L. major infected BALB/c mice served as control and parasite load was normalized to
mouse b-actin (Figure 1F). Error bars represent means 6 SEM (standard error of the mean). Significances between groups were analyzed in one-way
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uninfected controls did not proliferate after stimulation with
soluble Leishmania antigen (SLA) whereas spleen cells derived from
infected animals showed proliferation of CD4+ as well as CD8+ T
cells. The highest proliferation rate was induced by polyclonal
stimulation with phorbol myristate acetate (PMA) and Concanav-
alin A (ConA) (Figure 4B+C). Thus, human T cells are still
responsive to different stimuli even though they were embedded in
a murine environment.
Figure 2. Human-derived immune cells harbour Leishmania parasites in humanized mice. 42 days after high dose infection (36106 L.
major), liver spleen and the site of infection were analyzed for the host parasite interaction. Cryosections of liver (A), and spleen (B) biopsies were
stained for human CD45 (green), and Leishmania antigen (L-Ag, red). L. major-infected humanized mice appear in orange (CD45+ and L-Ag+
colocalization; white arrows). (C) Cryosections of footpad samples (site of infection) were stained for human CD68 (red), and L. antigen (L-Ag, green).
The insert C-I highlights infected human CD68+ macrophages. The insert C-II highlights infected CD682 cells. The blue-fluorescent DAPI nucleic acid
stain was added to all staining (blue; nuclei). Bars represent 50 mm.
doi:10.1371/journal.pntd.0001741.g002
Anova (A** = p = 0,0013). Additionally significances between groups are marked with ** (p,0,01) analyzed with Tukey’s Multiple Comparison Test.
Survival curve was analyzed by Log-rank (Mantel-Cox) Test (* = p,0,05).
doi:10.1371/journal.pntd.0001741.g001
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Furthermore, the cytokine response of splenocytes from infected
humanized mice was characterized. These data revealed that a
restimulation with SLA results in a significantly increased IFN-c
(Th1 type cytokine) production whereas IL-4 and IL-10 (Th2 type
cytokine) were hardly detectable (Figure 4D). The proinflamatory
cytokines TNF and IL-6 are not increased after restimulation with
SLA. Based on this cytokine profile we conclude that the
splenocytes release cytokines representing a Th1-type immune
response. In addition we tried to induce a DTH reaction in
humanized mice infected with L. major to measure the migration
capacity of Th1 type effector cell to the site of antigen inoculation
[42,43]. Remarkably, no clinical signs of swelling and redness
could be measured after subcutaneous injection of Leishmania
antigen (data not shown).
Leishmania major load in visceral organs can be reduced
by treatment with Miltefosine
Cutaneous leishmaniasis caused by L. major is characterized by
skin ulcers, papules or nodules. However, exceptions from these
classical cutaneous manifestations have been reported. Those
patients show unusual forms of cutaneous leishmaniasis with
abnormal liver function [39,44].
As already shown above humanized mice develop a sever course
of disease not sufficient to eliminate the parasites. Thus,
humanized mice might represent an experimental model for
Leishmania-caused disease, which do not show any self-healing
capacity. Accordingly, we tested a drug-based treatment against
the parasites in the humanized mouse model. We used Miltefosine
because it is already established for treatment of visceral and
cutaneous leishmaniasis [34].
To mimic the clinical situation, Miltefosine was given orally
starting at day 14 post infection when clinical signs such as swelling
and redness at the site of infection were detectable. Miltefosine
treatment of humanized and BALB/c mice did not reduce the
local inflammatory process at the site of infection (Figure 5A).
Nevertheless, humanized mice showed a reduced local inflamma-
tion at the site of infection compared to BALB/c. Furthermore,
BALB/c mice did not loose weight (with or without treatment)
whereas humanized mice lost weight when treated with Miltefo-
sine (Figure 5B). Additionally, only humanized mice treated with
Miltefosine revealed increased liver enzyme levels (Figure 5 C).
For the characterization of the therapy efficiency we quantified
the number of parasites in the organs of interest. These data
revealed that BALB/c mice show significant reduction of the
Figure 3. Flow cytometric analyses of human immune cells invading the infected footpad. (A) Infected footpad (36106 L. major) of a
humanized mouse is shown. (B) The invasion of human B cells (CD19) and human T cells (CD3) to the site of infection were determined (n = 3). (C) T
cells were further characterized for CD4+ T helper and CD8+ cytotoxic T cell subsets and (D) their naı¨ve (CD27+CD45RA+) and memory
(CD27+CD45RA2) phenotype. Significances between groups were analyzed using Student’s t test (* = p,0.05; ** = p,0.01, n = 3). Error bars represent
means 6 SEM (standard error of the mean).
doi:10.1371/journal.pntd.0001741.g003
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parasite load at the site of infection and visceral organs and bone
marrow (Figure 5E). In contrast the Miltefosine therapy in
humanized mice showed only slight reduction of the parasites in
the liver and footpad (Figure 5D). However, during Miltefosine
therapy we observed adverse effects, which are also described in
humans [34] such as weight loss (Figure 5B) and significantly
increased release of liver enzymes (GOT and GPT), which did not
occur in infected and treated BALB/c mice (Figure 5C).
Notably, Miltefosine treatment neither affected the overall
reconstitution, the T and B cell distribution nor the priming of
human T cells in the spleen (Figure S3A+B).
Discussion
Humanized mice in triple deficient NOD/scid-IL2c2/2 (NSG)
mice develop all cellular components of the human immune
system such as T, B, and NK cells as well as myeloid cells and are
able to mount an adaptive and innate immune response to
antigens [19,21]. Based on this innovative concept to create a
human immune system in a murine environment, scientific issues
regarding virus-caused infectious diseases [24,45–47], therapy and
vaccine studies [28–33], graft versus host disease (GvHD) [48],
and tumor diseases [37] were already studied.
To characterize the interactions between human immune cells
and obligatory intracellular protozoan parasites under in vivo
conditions we infected humanized mice with L. major parasites. In
general these parasites induce cutaneous leishmaniasis. However,
exceptions of this classic form with mild visceral tendency have
been reported in patients before [40,49–51]. This capacity for
visceralization was also described in L. tropica infected patients
[52].
The L. major strain (MHOM/IL/81/FE/BNI] used in our
experiments was isolated from a LCL patient [53]. Of note, under
experimental conditions this L. major strain can result in visceral
Figure 4. Flow cytometric analyses of human immune cells in the spleen affected by L. major infection. (A) Analyses of naı¨ve
(CD27+CD45RA+) and memory (CD27+CD45RA2) CD8+ (top) and CD4+ T cells in the spleen with (36106 L. major; n = 9) or without infection (n = 4). (B)
CFSE-labelled spleen cells isolated from L. major-infected humanized mice (36106 L. major; n = 3) and control humanized mice (HM; without in vivo L.
major infection; n = 2) re-stimulated with Leishmania major antigen (SLA), PMA or ConA for 72 hours. Cell samples were then analyzed for CD4+ T cell
(light grey), CD8+ T cells (grey) and B cells proliferation (dark grey). Percentage of human T cells of three individual humanized mice samples were
determined in C. (D) Human cytokine release from spleen cells (isolated from L. major-infected (36106) humanized mice; n = 3) restimulated with
soluble L. major antigen (SLA), PMA or without restimulation after 72 hours. pb = peripheral blood. Significances between groups were analyzed in
one-way (C) or two-way-Anova (A) (A* = p,0,05; A** = p,0,01; A**** = p,0,0001). Additionally significances between groups are marked with
* (p,0,05), ** (p,0,01), and *** (p,0,001) analyzed with Tukey’s Multiple Comparison Test (1-way-Anova) and Bonferroni posttest (2-way-Anova).
doi:10.1371/journal.pntd.0001741.g004
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Figure 5. Influences of Miltefosine treatment in infected humanized mice. Footpad swelling (A), weight change (B), and parasitic infestation
in different organs normalized to human b-actin (D) in L. major (36106 L. major) infected humanized mice with (n = 6) and without Miltefosine (n = 6)
treatment. BALB/c mice served as control (n = 3/group). (C) Alanine aminotransferase (ALT/GPT) and aspartate aminotransferase (AST/GOT) activities
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manifestations in resistant C57BL/6 and susceptible BALB/c mice
as well [50,54–60]. Thus, it cannot be generally excluded hat L.
major parasites might show the tendency of mild visceralization in
parallel to the cutaneous manifestation.
Here we questioned for the first time whether L. major parasites
can replicate within humanized mice. Furthermore, we tested this
novel experimental model - sharing murine and human compo-
nents – for its capacity to characterize human adaptive and innate
immune response to L. major and the efficiency of treatments like
such as hexadecylphosphocholine Miltefosine.
Initial experiments revealed that cutaneous inoculation of L.
major parasites resulted in an inflammation at the site of infection.
Additionally the severity of disease correlates with the dose of
parasites injected. Thus, humanized mice develop a local
inflammation caused by the protozoan parasites. Based on the
reconstitution of NSG mice with naı¨ve human leucocytes it is most
likely that human cells are involved in the parasite-induced
inflammatory response. Thus, we further investigated the pheno-
type and origin of potential host cells at the site of infection of
humanized mice. It is important to mention that humanized mice
still possess mouse myeloid cells such as macrophages and
granulocytes. And indeed, our data revealed that Leishmania-
antigens can be detected in human as well as murine myeloid cells
indicating that mouse myeloid cells represent target cells for
Leishmania in humanized mice. As suggested by several findings
infected mouse myeloid cells might function as a niche for
Leishmania allowing immune evasion. First, the human adaptive
immune system is not able to control or stimulate mouse immune
cells due to mismatched MHC expression and the species-
specificity of human IFN-c [61–64]. Second, most of those
myeloid mouse cells show functional weaknesses as for instance
insufficient differentiation of fully functional DC from NSG bone
marrow cells [21]. And third, it has been shown that in NOD-scid
mice the remaining mouse macrophages show an impaired
functionality [61].
However, we detected a 10-fold increase in the expression of
murine iNOS mRNA in the footpad tissue of humanized mice
three weeks after infection with L. major whereas no increase of
iNOS mRNA was found in the spleen. This clearly indicates that
mouse macrophages somehow get activated during infection,
although the upregulation of iNOS mRNA in humanized mice is
,factor 100 lower than that seen in infected BALB/c mice. In
accordance, no iNOS mRNA increase was visible in the spleen of
BALB/c mice upon infection [unpublished data, U. Schleicher
and C. Bogdan, Erlangen). With regard to parasite control this
lack of iNOS increase in the spleen is of minor importance as
rather NADPH-oxidase-dependent than iNOS-dependent mech-
anism are required for the resolution of the parasites in this organ
[65]. In contrast to mouse iNOS mRNA no induction of human
iNOS mRNA was detectable in infected humanized mice. Since
we demonstrated that human macrophages get infected in
humanized mice this result rather supports the idea that iNOS
expression by macrophages or other cells in response to infections
does not occur in the human immune system [15]. That this
statement might not hold true in human cutaneous leishmaniasis is
supported by results demonstrating iNOS mRNA and protein
expression in skin lesions of CL patients [11,66]. Together, it can
be therefore speculated that the atypical visceralisation of L. major
parasites within humanized mice might be at least partially due to
the insufficient production of murine derived leishmanicidal
molecules and the lack of human iNOS induction.
Considering that infected macrophages need to be activated by
an efficient Th1-cell response [67] the human-derived T cell
response was further analyzed. Inflammatory human T cells could
be detected at the site of infection. Most of them represent the
phenotype of a memory T cells and the majority of these cells
belong to the CD4+ T helper cell population, known to play a
major role in the activation of infected macrophages and
subsequent killing of the intracellular Leishmania parasites [68].
The fact that CD4+ as well as CD8+ T cells were efficiently primed
in vivo indicates that human antigen presenting cells are functional
and that the induced human T cell response is Leishmania-specific.
Based on the fact that splenocytes of infected humanized mice
respond with a pronounced human IFN-c production after
restimulation with soluble Leishmania antigen (SLA) we conclude
that a human Th1-like immune response was induced.
From the experimental model of leishmaniasis it is known that
resistant C57BL/6 mice develop a delayed hypersensitivity (DTH]
response after s.c. injection of SLA whereas susceptible BALB/c
mice do not show any signs of a DTH response [42,43]. This lack
of DTH reaction was also detectable in infected humanized mice
and might represent the dysfunction of the induced Th1-type
effector cells to get recruited to the site of antigen inoculation.
Based on the fact that humanized mice do not show signs of a
DTH reaction we can conclude that Th1 cells are efficiently
primed within the spleen but failed to migrate to the site of the
infection. This might also explain the relative low parasite density
within the spleen compared to the parasite load detectable at the
site of infection.
To investigate the versatility of our model for future drug
studies, we treated infected humanized mice and BALB/c mice
with Miltefosine. In BALB/c mice the application of Miltefosine
induced a reduction of the parasite load predominantly in visceral
organs such as liver and spleen in the absence of liver damage and
weight loss. In contrast humanized mice respond different to the
Miltefosine therapy. They show signs of liver damage and
significant weight loss after treamtent. Thus the Miltefosine-
derived side effect must be the consequence of the presence of
human immune cells. This is in agreement with published data
[69–70] demonstrating signs of liver toxicity in patients after
Miltefosine therapy. The observed Miltefosine-based side in
humanized nice might be due to the fact that Miltefosine can
activate human immune cells to release pro inflammatory
cytokines [71–72] that in turn cause the observed liver damage.
Thus, humanized might be a useful tool to test possible side effects
which are not detectable in classical animal models such as BALB/
c, before starting clinical trials.
The leishmanicidal effect of Miltefosine in humanized mice is
visible but not comparable to control BALB/c mice. This might be
due to the lack of mouse IFN-c which in turn can not activate
infected mouse macrophages.
in the serum were analyzed in non-infected humanized mice (HM; n = 7), humanized mice infected with L .major (36106 L. major) and treated with
Miltefosine (HM+Miltefosine; n = 6) and without (HM w/o Miltefosine; n = 14) and compared with BALB/c mice infected without Miltefosine (BALB/c w/
o Miltefosine; n = 3) and treated with Miltefosine (BALB/c+Miltefosine; n = 3). (D+E) All mice (BALB/c: n = 3/each group; humanized mice: numbers are
indicated above the columns for each organ) were sacrificed six weeks post infection before disease progression led to death of any of the animal.
For statistical analyses in A and B, area under the curve was calculated and analyzed using Student’s t test (* = P,0.05). Error bars represent means 6
SEM (standard error of the mean). Significances between groups were analyzed in one-way (C) and 2-way (D) Anova (A* = p,0,05). Additionally
significances between groups are marked with * (p,0,05) analyzed with Tukey’s Comparison Test.
doi:10.1371/journal.pntd.0001741.g005
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In conclusion, we have generated a novel Leishmania major
infection model using humanized mice which develop a systemic
non-self-healing disease. Humanized mice might therefore be
especially interesting for studies on visceral leishmaniases offering
an additional challenge for new treatment strategies: the elimina-
tion of resting (‘‘hiding’’) Leishmania parasites within the mouse
immune cells. In addition, side effects induced by activated human
immune cells (cytokine release) which do not occur in wild type
mice can now be illuminated in a small animal model which might
help to predict possible side effects before the drugs get tested in
clinical trials.
Supporting Information
Figure S1 Transplantation of human CD34+ into neo-
natal NSG mice resulted in stable human engraftment
throughout all organs. (A) Stable reconstitution of human
CD45+ cells was detectable in the peripheral blood in humanized
mice starting with the age of six weeks up to more than sixteen
weeks. (B) In humanized mice, transplantation of 36105 human
stem cells induces human engraftment (CD45+) and distribution in
all organs in the age between eight to sixteen weeks. (C) Further
immunohistological staining in different organs (here shown for
spleen) stained clusters of human hematopoietic cells (CD45),
human B cells (CD79A), human macrophages (CD68), and human
T cells (CD3).
(TIF)
Figure S2 Leishmania major infection in humanized
mice induced human innate immune response. (A, B)
Characterization of human dendritic cells (Lin2 CD11c+ HLA-
DR+) and (C) its activation status (CD86 and HLA-DR expression)
in the spleen with (+) and without (2) L. major infection. (D)
Relative mouse and human iNOS expression in spleen and
footpad (skin) of 3 weeks infected humanized mice were analyzed
by quantitative PCR. Error bars represent means 6 SEM
(standard error of the mean). Error bars represent means 6
SEM (standard error of the mean). Significances between groups
were analyzed in 1-way (B) and 2-way Anova (C). Significances
between groups (n = 3) are marked with * (p,0,05) and ** (p,0,01)
analyzed with Bonferroni posttest.
(TIF)
Figure S3 Miltefosine treatment did not have significant
influence on reconstitution level and immune cell
distribution in the spleen. Flow cytometric analyses of spleen
cells isolated from L. major infected humanized mice treated with
Miltefosine in comparison with not treated humanized mice
(Aqua). (A) Spleen cells were analyzed for total reconstitution level
(CD45+), T cells (CD3+) and B cells (CD19+). (B) T cells were
further characterized for CD4+ and CD8+ subsets and naı¨ve
(CD27+CD45RA+) and memory (CD27+CD45RA2) phenotype.
Error bars represent means 6 SEM (humanized mice+Miltefo-
sine; n = 6 and humanized mice+Aqua; n = 6).
(TIF)
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